MSH2 and cancer: Bladder urothelial cancer as an LS-related cancer is a subject of debate, but a study showed statistically significant differences in their frequencies, with more cancers in MSH2 mutation carriers (4.4%) compared to MSH6 (1.7%) or MLH1 (2.2%) mutation carriers [73].